Search

A new editorial paper published in Oncoscience discusses the use of tumor mutation burden (TMB) as a clinical biomarker for predicting the response to immunotherapy in urothelial carcinomas. High TMB has been associated with a positive response to immune checkpoint inhibitors, but not all cancers with high TMB or microsatellite instability (MSI) phenotype respond to immunotherapy. The paper suggests that combining immunotherapy with targeted therapies that address additional molecular defects present in urothelial carcinomas may offer a potential treatment option for immune checkpoint inhibitor-resistant urothelial carcinomas with high TMB and those with low TMB. [Extracted from the article]

A recent editorial paper published in Oncoscience discusses the challenges of developing novel therapeutics for metastatic tumors. The author highlights that tumors that have spread to distant locations, such as the brain, are difficult to treat and cure. While immunotherapeutic approaches have shown success in some tumor types, there is evidence that they may cause hyper-progression in certain patients. The paper emphasizes the need for combination therapies targeting key signaling pathways to effectively control tumor growth and survival. [Extracted from the article]

A recent research paper published in Oncotarget discusses the discovery of a potential biomarker, SSR3, that could predict the response to paclitaxel treatment in glioblastoma and breast cancer patients. The researchers used a whole genome CRISPR knockout screen to identify this biomarker, and it was validated in two independent breast cancer patient cohorts. The paper emphasizes the importance of validating novel biomarkers to improve the efficacy of therapeutic agents, particularly in the context of glioblastoma where treatment outcomes can be unpredictable. The researchers also highlight the need for further identification and validation of predictive biomarkers to enable personalized and precise medicine. [Extracted from the article]

A new editorial paper published in Oncotarget discusses acute myeloid leukemia (AML), a type of aggressive cancer. The paper highlights recent advancements in understanding AML biology and the potential for developing novel drug therapies. The researchers suggest exploring reductive carboxylation as a possible drug target to weaken tumor cell survival mechanisms and improve patient outcomes. The paper provides further information on this topic and can be accessed through the provided DOI link. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the therapeutic potential and challenges of cytostatic persister cancer cells. These cells are able to remain viable despite treatment and can contribute to residual diseases and the emergence of resistant clones and relapses. Unlike resistant cells, persister cancer cells enter a non-proliferating state that is reversible upon treatment discontinuation. The paper highlights the need to understand the properties of cytostatic persisters and explores strategies for targeting them to reduce cancer recurrence. The researchers suggest that administering multiple targeted regimens may be necessary to effectively deplete the persister reservoirs in patients undergoing cancer treatments. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the molecular functions of regulatory genetic variants associated with cancer. The paper highlights the challenges in understanding the effects of genetic variants, such as their small effect size and their location in non-protein-coding regions of the genome. The researchers propose integrating genomic, epigenomic, transcriptomic, and machine learning methods to identify functional genetic variants and characterize their mode of action in regulating target genes. This approach has implications for cancer research and precision medicine. [Extracted from the article]

A new editorial paper published in Oncotarget discusses the role of HER2 mutant alleles in breast cancer. The researchers explore the effects of individual HER2 mutant alleles on therapeutic response, the role of HER2 mutation in metastatic propensity, and differences in patient outcomes in different types of breast cancer. The paper also discusses the potential efficacy of the pan-HER inhibitor poziotinib as a therapeutic agent. The findings suggest that further studies are needed to evaluate poziotinib in different tumor types. [Extracted from the article]

A research paper titled "Cyclin D1 expression in penile cancer" was recently published in Oncotarget's Volume 15. The study, conducted by researchers from various universities in Brazil, aimed to analyze the expression of cyclin D1 in patients with penile cancer (PC) and determine its correlation with clinical and histopathological features. The study involved 100 PC patients and found that the absence of cyclin D1 expression was associated with HPV-positive histological subtypes, while its expression was associated with high-grade tumors, histological subtype, presence of sarcomatoid transformation, and perineural invasion. The researchers suggest that cyclin D1 may be a potential biomarker for PC, particularly for poorer prognosis. [Extracted from the article]

A research paper published in Aging suggests that chlorogenic acid, a major polyphenol found in Du-Zhong, a herb used in Traditional Chinese Medicine, may be a promising candidate for the treatment of osteoporosis. The study found that chlorogenic acid enhanced osteoblast functions and suppressed osteoclast formation, effectively preventing bone loss in ovariectomized rats. The researchers concluded that chlorogenic acid could potentially be developed into a novel anti-osteoporosis treatment. [Extracted from the article]

A research paper titled "Analytical validation of NeXT Personal(R), an ultra-sensitive personalized circulating tumor DNA assay" was published in Oncotarget's Volume 15 on March 14, 2024. The study describes the analytical validation of NeXT Personal(R), a circulating tumor DNA (ctDNA) assay that can detect residual disease, monitor therapy response, and detect recurrence in patients with solid tumor cancers. The assay uses whole genome sequencing and advanced analytics to accurately identify somatic variants specific to the patient's tumor. The validation study demonstrated high sensitivity, specificity, and precision of the assay. This study suggests that NeXT Personal has strong potential for clinical use in ctDNA monitoring of solid tumor cancers. [Extracted from the article]